Despite Early Promise GLP-1 Disappoints in Parkinson’s ...Middle East

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( Despite Early Promise GLP-1 Disappoints in Parkinson’s )

Also on site :

• Walmart Is Selling an 'Elegant' $142 Lancome Perfume for Only $43, and Shoppers Say It 'Makes Heads Turn'
• Syria group says military chief arrested in UAE
• CSK vs PBKS Match Prediction - Who Will Win Today's IPL Match 49 2025?